Efficacy and safety of risankizumab versus methotrexate in patients with moderate-to-severe plaque psoriasis: results from IMMbrace, a randomized, double-blind, phase 3 study with an open-label extension period in Brazil. - Cestari TF; Souza CDS; Azulay-Abulafia L; Romiti R; Carvalho AVE; Silva de Castro CC; Marques SA; Antonio JR; Fabrício L; Soliman AM; Wu T; Sinvhal R; et al. (Anais brasileiros de dermatologia, 2025)